#+TITLE: Laboratory Methods for Quantitative Acylcarnitines in Biological Matrices
#+AUTHOR: Matthew Henderson, PhD, FCACB
#+DATE: \today

:PROPERTIES:
#+DRAWERS: PROPERTIES
#+LaTeX_CLASS: beamer
#+LaTeX_CLASS_OPTIONS: [presentation, smaller]
#+BEAMER_THEME: Hannover
#+BEAMER_COLOR_THEME: whale
#+BEAMER_FRAME_LEVEL: 2
#+COLUMNS: %40ITEM %10BEAMER_env(Env) %9BEAMER_envargs(Env Args) %4BEAMER_col(Col) %10BEAMER_extra(Extra)
#+OPTIONS: H:2 toc:nil
#+PROPERTY: header-args:R :session *R*
#+PROPERTY: header-args :cache no
#+PROPERTY: header-args :tangle yes
#+STARTUP: beamer
#+STARTUP: overview
#+STARTUP: hidestars
#+STARTUP: indent
# #+BEAMER_HEADER: \subtitle{What is an Automated and Reproducible Report?}
#+BEAMER_HEADER: \institute[NSO]{Newborn Screening Ontario | The University of Ottawa}
#+BEAMER_HEADER: \titlegraphic{\includegraphics[height=1cm,keepaspectratio]{../logos/NSO_logo.pdf}\includegraphics[height=1cm,keepaspectratio]{../logos/cheo-logo.png} \includegraphics[height=1cm,keepaspectratio]{../logos/UOlogoBW.eps}}
#+latex_header: \hypersetup{colorlinks,linkcolor=white,urlcolor=blue}
#+LaTeX_header: \usepackage{textpos}
#+LaTeX_header: \usepackage{textgreek}
#+LaTeX_header: \usepackage[version=4]{mhchem}
#+LaTeX_header: \usepackage{chemfig}
#+LaTeX_header: \usepackage{siunitx}
#+LaTeX_header: \usepackage{gensymb}
#+LaTex_HEADER: \usepackage[usenames,dvipsnames]{xcolor}
#+LaTeX_HEADER: \usepackage[T1]{fontenc}
#+LaTeX_HEADER: \usepackage{lmodern}
#+LaTeX_HEADER: \usepackage{verbatim}
#+LaTeX_HEADER: \usepackage{tikz}
#+LaTeX_HEADER: \usetikzlibrary{shapes.geometric,arrows,decorations.pathmorphing,backgrounds,positioning,fit,petri}
:END:
#+BEGIN_LaTeX
%\logo{\includegraphics[width=1cm,height=1cm,keepaspectratio]{../logos/NSO_logo_small.pdf}~%
%    \includegraphics[width=1cm,height=1cm,keepaspectratio]{../logos/UOlogoBW.eps}%
%}

\vspace{220pt}
\beamertemplatenavigationsymbolsempty
\setbeamertemplate{caption}[numbered]
\setbeamerfont{caption}{size=\tiny}
% \addtobeamertemplate{frametitle}{}{%
% \begin{textblock*}{100mm}(.85\textwidth,-1cm)
% \includegraphics[height=1cm,width=2cm]{cat}
% \end{textblock*}}

\tikzstyle{chemical} = [rectangle, rounded corners, text width=5em, minimum height=1em,text centered, draw=black, fill=none]
\tikzstyle{hardware} = [rectangle, rounded corners, text width=5em, minimum height=1em,text centered, draw=black, fill=gray!30]
\tikzstyle{ms} = [rectangle, rounded corners, text width=5em, minimum height=1em,text centered, draw=orange, fill=none]
\tikzstyle{msw} = [rectangle, rounded corners, text width=7em, minimum height=1em,text centered, draw=orange, fill=none]
\tikzstyle{label} = [rectangle,text width=8em, minimum height=1em, text centered, draw=none, fill=none]
\tikzstyle{hl} = [rectangle, rounded corners, text width=5em, minimum height=1em,text centered, draw=black, fill=red!30]
\tikzstyle{box} = [rectangle, rounded corners, text width=5em, minimum height=5em,text centered, draw=black, fill=none]
\tikzstyle{arrow} = [thick,->,>=stealth]
\tikzstyle{hl-arrow} = [ultra thick,->,>=stealth,draw=red]

#+END_LaTeX

* Introduction
** Carnitine and Acylcarnitines

- Carnitine (\beta{}-hydroxy-\gamma{}-N-trimethylaminobutyric acid) is
  an endogenous quaternary ammonium compound synthesized from lysine
  and methionine.
- L-Carnitine has been described as a "conditionally essential"
  nutrient for humans.
- Populations with an exogenous carnitine requirement include:
  - infants (premature and full-term),
  - patients on long-term parenteral nutrition,
  - perhaps children.
- Exogenous carnitine is required to maintain "normal" (in the
  epidemiologic sense) plasma or serum carnitine concentrations in
  humans of all ages.
- Primary function is to shuttle long chain fatty acids to the
  mitochondrial matrix, for \beta{}-oxidation.
- Acylcarnitines are markers for FAODs and OAs
\vspace{2em}
#+BEGIN_LaTeX
\centering
\chemname{\chemfig[][scale=.5]{H3C-N^{+}([2]-CH3)([6]-CH3)-CH2-C([2]-H)([6]-OH)-CH_2-C([1]=O)([7]-O^{-})}}{\tiny Carnitine}
\hspace{3em}
\chemname{\chemfig[][scale=.5]{H3C-N^{+}([2]-CH3)([6]-CH3)-CH2-C([2]-H)([6]-O-C([0]=O)-{\color{red}R})-CH_2-C([1]=O)([7]-O^{-})}}{\tiny Acylcarnitine}
%\chemname{\chemfig[][scale=.5]{H3C-N^{+}([2]-CH3)([6]-CH3)-CH2-C([2]-H)([6]-O-C([0]=O)-{\color{red}R})-CH_2-C([2]=O)-O-CH_2-CH_2-CH_2-CH_3}}{\tiny Acylcarnitine, butyl ester}
#+END_LaTeX

** Sample Type
- Plasma
  - Diagnostic testing for FAODs and OAs
  - Monitoring
- Dried blood spot
  - Newborn Screening for FAODs and OAs
- Urine
  - Diagnosis of CUD
** COMMENT ERNDIM Plasma Acylcarnitines Survey
#+CAPTION: Free Carnitine
#+ATTR_LATEX: :height 0.8\textheight
[[./figures/free_carnitine_erndim.png]]

** COMMENT ERNDIM Plasma Acylcarnitines Survey
#+CAPTION: Acetylcarnitine
#+ATTR_LATEX: :height 0.8\textheight
[[./figures/acetylcarnitine_erndim.png]]


* Screening FIA-MS/MS
** FIA-MS/MS schematic
#+BEGIN_LaTeX
\begin{center}
\begin{tikzpicture}[node distance=7em]
% nodespp
\node(ms1)[ms]{MS1: Mass Filter};
\node(cc)[ms, right of=ms1]{Collision cell};
\node(ms2)[ms, right of=cc]{MS2: Mass Filter};
\node(ion)[ms, below of=ms1,yshift=3em]{Ionization};
\node(lc)[msw, below of=ion,yshift=3em]{Injection};
\node(detector)[ms, below of=ms2, yshift=3em]{Detector};
% arrows
\draw[arrow](lc) -- (ion);
\draw[arrow](ion) -- (ms1);
\draw[arrow](ms1) -- (cc);
\draw[arrow](cc) -- (ms2);
\draw[arrow](ms2) -- (detector);
\end{tikzpicture}
\end{center}
#+END_LaTeX

- Solvent delivery is via HPLC with no chromatography
- 10 \micro{}L of sample extract is injected into a flowing stream operating at ~0.15 ml/min.

- Typical injection rates between samples are 2 min, giving a potential 400
  to 600 sample capacity per instrument per day.
  - volume is typically 200-400 specimens per instrument per day
  - maintenance issues, repeat specimen analysis.

** FIA-MS/MS sample 
- Acylcarnitines in the DBS eluate are esterified as butyl esters with butanol-3M HCL

#+BEGIN_LaTeX
\definesubmol{x}{-[1,.6]-[7,.6]}
\definesubmol{y}{-[7,.6]-[1,.6]}
\definesubmol{d}{!y!y-[7,.6]{\color{red}COOH}}
\definesubmol{e}{!y!y}
\centering
\schemedebug{false}
\schemestart
\chemname{\chemfig[][scale=.33]{-N^{+}([2]-)([6]-)-[1]-[7]([6]-O-([5]=O)!e)-[1]-[7]([7]=O)([1]-O^{-})}}{\tiny C5-carnitine}
\+
\chemname{\chemfig[][scale=.33]{HO!x!x}}{\tiny n-butanol}
\arrow{-U>[][{\tiny \ce{H2O}}]}
\chemname{\chemfig[][scale=.33]{-N^{+}([2]-)([6]-)-[1]-[7]([6]-O-([5]=O)!e)-[1]-[7]([6]=O)-[1,.6]O!y!y}}{\tiny C5-carnitine, butyl ester}
\schemestop
\vspace{2em}
\schemedebug{false}
\schemestart
\chemname{\chemfig[][scale=.33]{-N^{+}([2]-)([6]-)-[1]-[7]([6]-O-([5]=O)!d)-[1]-[7]([7]=O)([1]-O^{-})}}{\tiny C6DC-carnitine}
\+
\chemname{\chemfig[][scale=.33]{HO!x!x}}{\tiny n-butanol}
\arrow{-U>[][{\tiny \ce{2H2O}}]}
\chemname{\chemfig[][scale=.33]{-N^{+}([2]-)([6]-)-[1]-[7]([6]-O-([5]=O)!e-[7,.6]O!x!x)-[1]-[7]([6]=O)-[1,.6]O!y!y}}{\tiny C6DC-carnitine, butyl ester}
\schemestop 
#+END_LaTeX

** FIA-MS/MS Method

- Electrospray ionization in positive mode
- Butylated acylcarnitines fragment to produce a characteristic ion with mass of 85 Da. 
- A precursor ion scan is used to identify molecules that fragment to form a 85 m/z molecule.

*** Precursor Ion Scan
#+BEGIN_LaTeX
\begin{center}
\begin{tikzpicture}
\node[box](ms1)[]{};
\node[label](ms1u)[above=of ms1,yshift=-3em]{MS1};
\node[label](ms1l)[below=of ms1,yshift=3em]{scanning};
\node[box](cc)[right= of ms1]{};
\node[label](ccu)[above=of cc,yshift=-3em]{Collision cell};
\node[label](ccl)[below=of cc,yshift=3em]{fragmentation};
\node[box](ms2)[right= of cc]{};
\node[label](ms2u)[above=of ms2,yshift=-3em]{MS2};
\node[label](ms2l)[below=of ms2,yshift=3em]{85 m/z};
\draw[->](ms1) -- (cc);
\draw[->](cc) -- (ms2);

%ms1
\draw [gray,->, decorate,decoration=snake] (-.8,0.5) -- (.8,0.5);
\draw [gray,->, decorate,decoration=snake] (-.8,0.25) -- (.8,0.25);
\draw [blue, ->,decorate,decoration=snake] (-.8, 0) -- (.8,0);
\draw [gray,->, decorate,decoration=snake] (-.8,-0.25) -- (.8,-0.25);
\draw [gray,->,decorate,decoration=snake] (-.8,-0.5) -- (.8,-0.5);

%cc
\draw [blue,->,decorate,decoration=snake] (2.1, 0) -- (2.4,0);
\fill (2.6,0) circle (0.1); 
\draw [gray,->,decorate,decoration=snake] (2.8, 0) -- (3.8,0.5);
\draw [red, ->,decorate,decoration=snake] (2.8, 0) -- (3.8,0);
\draw [gray,->,decorate,decoration=snake] (2.8, 0) -- (3.8,-0.5);

%ms2
\draw [red,->,decorate,decoration=snake] (5.1, 0) -- (6.8,0);
\end{tikzpicture}
\end{center}
#+END_LaTeX


** Fragmentation
#+BEGIN_LaTeX
\definesubmol{x}{-[1,.6]-[7,.6]}
\centering
 \chemname{\chemfig[][scale=.33]{H_{3}C-N^{+}([2]-CH_3)([6]-CH_{3})-CH_2-C([2]-H)([6]-O-C([0]=O)-{\color{red}R})-CH_2-C([2]=O)-O-CH_2-CH_2-CH_2-CH_3}}{\tiny acylcarnitine, butyl ester}

\vspace{2.5em}

 \chemname{\chemfig[][scale=.33]{H_{3}C-N([1]-CH_3)([7]-CH_3)}}{\tiny trimethylamine}
\hspace{2em}
\chemname{\chemfig[][scale=.33]{{\color{red}R}-C([1]=O)([7]-OH)}}{\tiny carboxylic acid}
\hspace{2em}
 \chemname{\chemfig[][scale=.33]{H!x!x}}{\tiny butyl group}
\hspace{2em}
 \chemname{\chemfig[][scale=.33]{H_{2}C^{+}-HC=CH-C([1]=O)([7]-OH)}}{\tiny 85 m/z}
#+END_LaTeX

** Overestimation of Free Carnitine

- Butylated acylcarnitines are converted to butylated carnitine in
  n-butanol-3M HCl at 65\degree{}C. [fn:johnson]

| Acyl Carnitine | Half-life (min) |
|----------------+-----------------|
| C2             |              31 |
| C10            |             125 |
| C18            |             172 |

- 65\degree{}C for 15 min.  
- NSO uses 60\degree{}C for 20 minutes.
- IMD uses 55\degree{}C for 20 minutes.

- In a sample with low free carnitine and high acetylcarnitine.
  - 30% of the acetylcarnitine and smaller amounts of higher
    molecular mass acylcarnitines are converted to carnitine
  - a low carnitine sample could appear to be normal.
- "The free carnitine results obtained by this screening method on
  blood spots with high levels of acylcarnitines should therefore be
  used with caution." [fn:johnson]

[fn:johnson] Johnson, D. W. (1999). Inaccurate measurement of free
carnitine by the electrospray tandem mass spectrometry screening
method for blood spots. Journal of Inherited Metabolic Disease, 22(2),
201â€“202. 
** TODO Free and Total Carnitine
- Method?
*** Fractional Tubular Re-absorption of Carnitine

#+BEGIN_LaTeX
\begin{equation*}
FTR_{carnitine}\% = \left( 1 -  \frac{carnitine_{urine} \cdot creatinine_{plasma}}{carnitine_{plasma} \cdot creatinine_{urine}}\right) \cdot 100
\end{equation*}
#+END_LaTeX

- normally >98%, \Downarrow in CUD

*** Free/Total Carnitine

\[
\frac{Free_{carnitine}}{Total_{carnitine}} = \frac{C_0}{\sum_{0}^{18} C_n}
\]

- \Downarrow in CUD, < 5-10% of normal 


** Why derivatize?

[[./figures/ionization.png]]

** MRM is used to detected dicarboxylic acylcarnitines

- C0-Bu 218.1 Da \to 103 Da transition is optimal
- All others benefit from the added sensitivity of MRM mode as compared to parent ion scan

\small
| Compound | Reaction        |
|----------+-----------------|
| C0       | 218.10 > 103.00 |
| C0 IS    | 227.10 > 103.00 |
| C2       | 260.20 > 85.00  |
| C2 IS    | 263.20 > 85.00  |
| C3       | 274.20 > 85.00  |
| C3 IS    | 277.20 > 85.00  |
| C3DC     | 360.30 > 85.00  |
| C4DC     | 374.30 > 85.00  |
| C5DC     | 388.35 > 85.00  |
| C5DC IS  | 391.35 > 85.00  |
| C6DC     | 402.45 > 85.00  |
| C8DC     | 430.45 > 85.00  |

** FIA-MS/MS Acylcarnitine Scan
*** Quantified Acylcarnitines
****                                                               :BMCOL:
:PROPERTIES:
:BEAMER_col: 0.3
:END:
- C0
- C2
- C3
- C3DC
- C4
- C4DC
- C5
- C5:1
- C5DC
- C5-OH
- C6
- C6DC
****                                                               :BMCOL:
:PROPERTIES:
:BEAMER_col: 0.3
:END:
- C8
- C8:1
- C10
- C10:1
- C12
- C12:1
- C14
- C14:1
- C14:2
- C14-OH
****                                                               :BMCOL:
:PROPERTIES:
:BEAMER_col: 0.3
:END:
- C16
- C16:1
- C16:1-OH
- C16-OH
- C18
- C18:1
- C18:1-OH
- C18:2
- C18-OH
** Pros and Cons of Butanol  FIA-MSMS for Aceylcarnitines
*** Pros
- Speed
- Sensitivity
- Expertise
- Amino acid measurement
*** Cons
- Isobaric compounds
  - C5DC and C10-OH
- Overestimation of CO due to hydrolysis

* COMMENT Diagnostic FIA-MS/MS
** Diagnostic FIA-MS/MS schematic
#+BEGIN_LaTeX
\begin{center}
\begin{tikzpicture}[node distance=7em]
% nodes
\node(ms1)[ms]{MS1: Mass Filter};
\node(cc)[ms, right of=ms1]{Collision cell};
\node(ms2)[ms, right of=cc]{MS2: Mass Filter};
\node(ion)[ms, below of=ms1,yshift=3em]{Ionization};
\node(lc)[msw, below of=ion,yshift=3em]{Fused silica};
\node(detector)[ms, below of=ms2, yshift=3em]{Detector};
% arrows
\draw[arrow](lc) -- (ion);
\draw[arrow](ion) -- (ms1);
\draw[arrow](ms1) -- (cc);
\draw[arrow](cc) -- (ms2);
\draw[arrow](ms2) -- (detector);
\end{tikzpicture}
\end{center}
#+END_LaTeX
- ESI in positive mode
** Inlet table                                                     :noexport:
#+tblname: data-table
| Time |  Flow |  %A | %B |
|------+-------+-----+----|
|    0 |  1.00 | 100 |  0 |
|  0.3 | 0.095 | 100 |  0 |
|  1.2 | 0.100 | 100 |  0 |
| 1.55 | 0.500 | 100 |  0 |
| 1.85 | 0.100 | 100 |  0 |
|  2.5 | 0.100 | 100 |  0 |

** FIA-MS/MS sample prep
- 20 \micro{}L of sample is mixed with 400 \micro{}L of IS in Methanol centrifuge to deproteinize.
- supernatant is removed and 100 \micro{}L of n-butanol-3M HCL is added
- dried down
- reconstituted with 200 \micro{}L 80% acetonitrile.
- 7.5 \micro{}L injection.

#+begin_src gnuplot :var data=data-table :file ./figures/outletmethod.pdf
reset
set title "UPLC Method"
set key on
set xlabel "min"

set xrange [0:3]

set ylabel "ml/min"
set yrange [0:1.2]

plot data u 1:2 w lp lw 2 t "80% ACN"

#+end_src

#+ATTR_LATEX: :width 0.7\textwidth
#+RESULTS:
[[file:./figures/outletmethod.pdf]]

** FIA-MS/MS transitions
*** Quantified acetylcarnitines
\tiny

****                                                               :BMCOL:
:PROPERTIES:
:BEAMER_col: 0.33
:END:

- C2 (ACETYL)
- C3:1 (PROPENYL)
- C3 (PROPIONYL)
- C4 (BUTYRYL)
- C5:1 (TIGLYL)
- C5 (ISOVALERYL)
- C4-OH (3OH-BUTYRYL)
- C6 (HEXANOYL)
- C5-OH/2ME3-OH BUTYRYL	
- BENZOYL
- C6-OH (3OH-HEXANOYL)	
- PHENYLACETYL	
- C8:1 (OCTENOYL)
- C8 (OCTANOYL)	

****                                                               :BMCOL:
:PROPERTIES:
:BEAMER_col: 0.33
:END:


- C3DC (MALONYL)
- C10:3 (DECATRIENOYL)
- C10:2 (DECADIENOYL)
- C10:1 (DECENOYL)
- C10 (DECANOYL)
- C4DC (MEMALONYL/SUCCINYL) 
- C5DC (GLUTARYL)/C10-OH
- C12:1 (DODECENOYL)
- C12 (DODECANOYL)
- C6:DC/3 MEGLUTARYL
- C12OH (3 OH DODECANOYL)
- C14:2 (TETRADECADIENOYL)
- C14:1 (TETRADECENOYL)
- C14 (TETRADECANOYL)
- C8DC

****                                                               :BMCOL:
:PROPERTIES:
:BEAMER_col: 0.33
:END:

- C14-1OH (3OH TETRADECENYL)
- C14-OH (3OH TETRADECANOYL)
- C16:1 (PALMITOLEYL)
- C16 (PALMITOYL)
- C10DC (SEBACYL)
- C16-1OH (3OH PALMITOLEYL)
- C16OH (3OH PALMITOYL)
- C18:2 (LINOLEYL)
- C18:1 (OLEOYL)
- C18 (STEAROYL)
- C18:2OH (3OH LINOLEYL)
- C18:1OH (3OH OLELYL)
- C18OH (3OH STEAROYL)
- C16DC	
- C18:1DC


* TODO Free and Total Carnitine
- Method?
** Fractional Tubular Re-absorption of Carnitine

#+BEGIN_LaTeX
\begin{equation*}
FTR_{carnitine}\% = \left( 1 -  \frac{carnitine_{urine} \cdot creatinine_{plasma}}{carnitine_{plasma} \cdot creatinine_{urine}}\right) \cdot 100
\end{equation*}
#+END_LaTeX

- normally >98%, \Downarrow in CUD

** Free/Total Carnitine

\[
\frac{Free_{carnitine}}{Total_{carnitine}} = \frac{C_0}{\sum_{0}^{18} C_n}
\]

- \Downarrow in CUD, < 5-10% of normal 

